How to control lymphangiogenesis: a novel role for rapamycin.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 17429417.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Analysis of the lymphatic microvasculature has become possible only recently by the discovery of novel proteins specifically expressed in lymphatic endothelial cells only. Therapeutic manipulation of de novo lymphangiogenesis might become clinically relevant in the future in diverse situations, such as renal transplant rejection. In this issue Huber et al. demonstrate that rapamycin acts as an efficient inhibitor of lymphangiogenesis.
Medical subject headings
- Immunosuppressive Agents
- Lymphangiogenesis
- Sirolimus